<DOC>
	<DOCNO>NCT01209299</DOCNO>
	<brief_summary>RATIONALE : Studying sample tissue laboratory patient receive carboplatin paclitaxel without sorafenib tosylate may help doctor learn effect treatment cell . It may also help doctor understand well patient respond treatment . PURPOSE : This research study study biomarkers predict response chemotherapy patient advance metastatic melanoma previously treat carboplatin paclitaxel without sorafenib tosylate .</brief_summary>
	<brief_title>Biomarkers Predicting Response Chemotherapy Patients With Advanced Metastatic Melanoma Previously Treated With Carboplatin Paclitaxel With Without Sorafenib Tosylate</brief_title>
	<detailed_description>OBJECTIVES : - To independently correlate gene expression promoter methylation profile chemotherapy response patient advance metastatic melanoma treat carboplatin paclitaxel versus without sorafenib clinical trial ECOG-E2603 . - To develop predictive model chemotherapy response utilize integrate analysis gene expression promoter methylation data . - To evaluate whether NER pathway haplotypes associate platinum drug resistance survival . OUTLINE : This multicenter study . Archived paraffin-embedded tissue sample analyze gene expression promoter methylation profile , gene involve NER pathway .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis melanoma Unresectable locally advance stage IV disease Received carboplatin paclitaxel versus without sorafenib clinical trial ECOGE2603 Archived paraffinembedded tissue sample Responder ( complete partial response , stable disease ) nonresponder ( disease progression unavailable ) PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>